Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design.
Viegas EO, Kroidl A, Munseri PJ, Missanga M, Nilsson C, Tembe N, Bauer A, Joachim A, Joseph S, Mann P, Geldmacher C, Fleck S, Stöhr W, Scarlatti G, Aboud S, Bakari M, Maboko L, Hoelscher M, Wahren B, Robb ML, Weber J, McCormack S, Biberfeld G, Jani IV, Sandström E, Lyamuya E; TaMoVac study group.
Viegas EO, et al. Among authors: weber j.
PLoS One. 2018 Nov 29;13(11):e0206838. doi: 10.1371/journal.pone.0206838. eCollection 2018.
PLoS One. 2018.
PMID: 30496299
Free PMC article.
Clinical Trial.